← All trials
NCT06049927
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- May 31, 2024
- First posted
- Sep 22, 2023
- Last posted
- Oct 2, 2023
- Enrollment
- 3300
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinovac Biotech Co., LtdLead sponsor
- Government of ChinaOverall official - principal investigator
- Government of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.